Astria Therapeutics Inc (209A.BE)
| Previous close | 1.0660 |
| Open | 1.0660 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.0660 - 1.0660 |
| 52-week range | 1.0660 - 1.0660 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Business WireAstria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
BOSTON, May 09, 2024--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
Business WireAstria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
BOSTON, May 08, 2024--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present information on the preclinical profile of STAR-0310 at the upcoming Society for Investigative Dermatology (SID) Annual Meeting in Dallas, Texas on May 16, 2024.
